Drug Trial Radar · NCT01962415
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Last checked: Nov 20, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Feb 4, 2014
Primary completion
Nov 2026
Study completion Nov 2027
Sponsor
- Lead sponsor
- Paul SzabolcsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 14, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 months, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). After transplant, subjects will be followed for late effects and for ongoing graft success.
Conditions
- Primary Immunodeficiency (PID)
- Congenital Bone Marrow Failure Syndromes
- Inherited Metabolic Disorders (IMD)
- Hereditary Anemias
- Inflammatory Conditions
- Systemic Juvenile Idiopathic Arthritis (sJIA)
- Juvenile Rheumatoid Arthritis (JRA)
Interventions
HydroxyureaDrug
Oral administration
AlemtuzumabDrug
Intravenous (IV) administration.
FludarabineDrug
IV administration
MelphalanDrug
IV administration
ThiotepaDrug
IV administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Post-transplant treatment-related mortality (TRM)Time frame: 1 year post-transplant
- Neurodevelopmental milestonesTime frame: 1 year post-transplant
- Immune ReconstitutionTime frame: 1 year post-transplant
- Severe opportunistic infectionsTime frame: 1 year post-transplant
- GVHD occurrenceTime frame: 1 year post-transplant
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.